Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 5/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 5/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5105016 | 0.90 | SMN1; SMN2 (0.49) | APPSMN1; SMN2NPC1RAB9ATMEM97 | |
| SCHEMBL6610559 | 0.76 | PARP1 (0.37) | PARP1SMN1; SMN2NPC1RAB9APDE4B | |
| SCHEMBL6610557 | 0.76 | PARP1 (0.37) | PARP1SMN1; SMN2NPC1RAB9APDE4B | |
| SCHEMBL12052572 | 0.73 | NPC1 (0.51) | PARP1SMN1; SMN2NPC1RAB9ASIGMAR1 | |
| SCHEMBL1441223 | 0.70 | SMN1; SMN2 (0.59) | SMN1; SMN2NPC1RAB9APDE4BHSD11B1 | |
| SCHEMBL20129713 | 0.70 | SMN1; SMN2 (0.59) | SMN1; SMN2NPC1RAB9APDE4BHSD11B1 | |
| SCHEMBL29332889 | 0.70 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9APDE4BHSD11B1 | |
| SCHEMBL2180966 | 0.70 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9APDE4BHSD11B1 | |
| SCHEMBL3277860 | 0.70 | SMN1; SMN2 (0.71) | PARP1SMN1; SMN2NPC1RAB9APDE4B | |
| SCHEMBL204145 | 0.70 | SMN1; SMN2 (0.71) | PARP1SMN1; SMN2NPC1RAB9APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7452906-B2 | Pyridine derivatives as Raf kinase inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-11-18 | — | — | US | disclosed |
| EP-1423384-B1 | PYRIDINE DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2007-05-23 | — | — | EP | disclosed |
| US-20040235843-A1 | Pyridine derivatives as raf kinase inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-11-25 | — | — | US | disclosed |
| EP-1423384-A1 | PYRIDINE DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003022840-A1 | PYRIDINE DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235843-A1 | Pyridine derivatives as raf kinase inhibitors | BRAF, RAF1, ARAF | APP 776/4885PARP1 1152/4885SMN1; SMN2 2498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.